REG - GSK PLC - EU authorisation of GSK’s RSV vaccine Arexvy

GSKAnnouncement

07/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230607:nRSG8767Ba&default-theme=true

RNS Number : 8767B  GSK PLC  07 June 2023

Issued: 7 June 2023, London UK

 

European Commission authorises GSK's Arexvy, the first respiratory syncytial
virus (RSV) vaccine for older adults

 

·   Authorisation will help protect adults 60 years of age and older in 30
European countries* from RSV disease for the first time

·   In Europe, RSV leads to over 270,000 hospitalisations and approximately
20,000 in-hospital deaths in adults 60 years of age and older each year

·   The authorisation is based on phase III efficacy data in older adults

 

GSK plc (LSE/NYSE: GSK) today announced that the European Commission has
authorised Arexvy (respiratory syncytial virus vaccine, adjuvanted) for active
immunisation for the prevention of lower respiratory tract disease (LRTD)
caused by respiratory syncytial virus (RSV) in adults 60 years of age and
older. This is the first time an RSV vaccine for older adults has been granted
European Marketing Authorisation. The first launches are planned ahead of the
2023/2024 RSV season which typically starts in the autumn.

 

Tony Wood, Chief Scientific Officer, GSK, said: "Thousands of older adults
across Europe suffer serious respiratory illness due to RSV each year. This
authorisation for Arexvy means eligible adults can be vaccinated against RSV
disease for the first time, reinforcing GSK's long history of vaccine
innovation. Our strong manufacturing capability and scale, including from our
vaccine manufacturing site in Belgium, means we are ready to deliver the
vaccine as countries begin to launch."

 

RSV is a common, contagious respiratory virus that leads to over 270,000
hospitalisations and approximately 20,000 in-hospital deaths each year in
adults aged 60 years and over in Europe(1). An estimated 3 million cases of
RSV acute respiratory infection (ARI) are reported in this population each
year, and the impact on healthcare systems is expected to increase as the
population ages(1). Those with underlying medical conditions, such as diabetes
and chronic heart and lung disease, drive the majority of RSV
hospitalisations.(2,3)

 

Dr Alberto Papi, Full Professor of Respiratory Medicine and Head at the
University of Ferrara, said: "For most, RSV causes cold-like symptoms. For
older adults and those with underlying medical conditions however, it can lead
to severe disease and is a leading cause of serious respiratory infections. As
scientists, we have been trying to find a solution for over 60 years. I am
proud to have been part of the innovation that has resulted in a vaccine now
being available to help protect eligible older adults across Europe from
severe RSV disease for the first time."

 

The authorisation is based on GSK's landmark positive pivotal AReSVi-006
(Adult Respiratory Syncytial Virus) phase III trial data. In the trial, the
vaccine showed statistically significant and clinically meaningful overall
efficacy of 82.6% (96.95% CI, 57.9-94.1, 7 of 12,466 vs 40 of 12,494) against
RSV-LRTD in adults aged 60 years and older, meeting the primary endpoint. In
addition, efficacy was 94.6% (95% CI, 65.9-99.9, 1 of 4,937 vs 18 of 4,861) in
older adults with at least one underlying medical condition of interest, such
as certain cardiorespiratory and endocrine-metabolic conditions.

 

The vaccine was generally well tolerated. The most frequently observed
solicited adverse events were injection site pain, fatigue, myalgia, headache,
and arthralgia. These were generally mild to moderate and transient.

 

The European Commission's decision follows the European Medicines Agency's
Committee for Medicinal Products for Human Use (CHMP) positive opinion in
April 2023. GSK's marketing authorisation application was reviewed under the
accelerated assessment mechanism because prevention of RSV disease in the
older adult population is considered a major public health interest.

 

Arexvy was the world's first RSV vaccine to be approved for older adults when,
in May 2023, it was approved by the US Food and Drug Administration. Later
this month, the Advisory Committee on Immunization Practices (ACIP) will make
recommendations on the appropriate use of the vaccine in the US. Regulatory
reviews are ongoing in Japan and several other countries.

 

About Arexvy (Respiratory Syncytial Virus (RSV) vaccine (recombinant,
adjuvanted))

Respiratory syncytial virus vaccine, adjuvanted, contains recombinant
glycoprotein F stabilised in the prefusion conformation (RSVPreF3). This
antigen is combined with GSK's proprietary AS01(E) adjuvant.

 

Indication

The European Commission has authorised Arexvy for active immunisation for the
prevention of LRTD caused by RSV in adults aged 60 years and older. It is also
approved in the US. The use of this vaccine should be in accordance with
official recommendations. As with any vaccine, a protective immune response
may not be elicited in all vaccinees.

 

The vaccine is not approved anywhere else in the world. The proposed trade
name remains subject to regulatory approval in other markets.

 

The Arexvy EMA Reference Information, including a full list of adverse events
and the complete important safety information in the EU, will shortly be
available at this link: www.ema.europa.eu/medicines/human//EPAR/arexvy

 

A clinical trial investigating RSV vaccination in adults aged 50-59, including
participants with underlying comorbidities, is fully recruited. Results are
expected in 2023, together with additional results from the AReSVi-006 phase
III efficacy trial and the AReSVi-004 immunogenicity trial. These trials
continue to evaluate an annual revaccination schedule and
protection/immunogenicity over multiple seasons following one dose of the RSV
vaccine.

 

The GSK proprietary AS01 adjuvant system contains QS-21 STIMULON adjuvant
licensed from Antigenics Inc, a wholly owned subsidiary of Agenus Inc.

 

About AReSVi-006

This is a randomised, placebo-controlled, observer-blind, multi-country phase
III trial to demonstrate the efficacy of a single dose of GSK's adjuvanted
RSVPreF3 vaccine in adults aged 60 years and above. Approximately 25,000
participants were enrolled from 17 countries. Initial results were published
in the New England Journal of Medicine
(https://www.nejm.org/doi/full/10.1056/NEJMoa2209604) in February 2023.

 

About RSV in older adults

RSV is a common contagious virus affecting the lungs and breathing passages.
Older adults are at high risk for severe disease due in part to age-related
decline in immunity. Older adults with underlying medical conditions are at
even greater risk for severe disease. RSV can exacerbate conditions, including
chronic obstructive pulmonary disease (COPD), asthma, and chronic heart
failure and can lead to severe outcomes, such as pneumonia, hospitalisation,
and death. In Europe, RSV leads to over 270,000 hospitalisation and
approximately 20,000 in-hospital deaths each year in adults aged 60 years and
over (1). Adults with underlying conditions are more likely to seek medical
services and have higher hospitalisation rates than adults without these
conditions.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Simon Moore        +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Alison Hunt        +1 540 742 3391       (Washington DC)

 Investor Relations:  Nick Stone         +44 (0) 7717 618834   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Josh Williams      +44 (0) 7385 415719   (London)
                      Camilla Campbell   +44 (0) 7803 050238   (London)
                      Steph Mountifield  +44 (0) 7736 063933   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include but are not limited to those described under
Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2022,
GSK's Q1 Results for 2023 and any impacts of the COVID-19 pandemic.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

Notes

* The European Commission has the authority to approve medicines for European
Union member states, as well as in the European Economic Area (EEA) countries
Iceland, Norway and Liechtenstein.

 

References

1.     Savic M, Penders Y, Shi T, Branche A, Pirçon J-Y. Respiratory
syncytial virus disease burden in adults aged 60 years and older in
high-income countries: a systematic literature review and meta-analysis.
Influenza Other Respir Viruses 2022 November 11.

Available at: https://onlinelibrary.wiley.com/doi/full/10.1111/irv.13031

2.     Centers for Disease Control and Prevention. RSV in Older Adults and
Adults with Chronic Medical Conditions. Accessed March 2023.

Available at: www.cdc.gov/rsv/high-risk/older-adults.html

3.     Tseng HF, Sy LS, Ackerson B, et al. Severe morbidity and short- and
mid- to long-term mortality in older adults hospitalized with respiratory
syncytial virus infection. J Infect Dis. 2020;222(8):1298-1310.
doi:10.1093/infdis/jiaa361.  

Available at: https://pubmed.ncbi.nlm.nih.gov/32591787/

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUNSUROVUNRUR